ebastine
E850018
H1 receptor antagonist
non-sedating antihistamine
pharmaceutical drug
second-generation antihistamine
Ebastine is a second-generation, non-sedating antihistamine used primarily to treat allergic rhinitis and chronic urticaria.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ebastine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10214839 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ebastine Context triple: [CYP2J2, metabolizes, ebastine]
-
A.
Zyrtec
Zyrtec is a widely used over-the-counter antihistamine medication primarily taken to relieve allergy symptoms such as sneezing, runny nose, and itchy or watery eyes.
-
B.
Allegra
Allegra is a widely used over-the-counter antihistamine medication for relieving allergy symptoms such as sneezing, runny nose, and itchy or watery eyes.
-
C.
Benadryl
Benadryl is a widely used over-the-counter antihistamine medication commonly taken to relieve allergy symptoms such as sneezing, itching, and runny nose.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Auscitain
An Auscitain is a resident or native of Auch, a historic town in the Occitanie region of southwestern France.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ebastine Target entity description: Ebastine is a second-generation, non-sedating antihistamine used primarily to treat allergic rhinitis and chronic urticaria.
-
A.
Zyrtec
Zyrtec is a widely used over-the-counter antihistamine medication primarily taken to relieve allergy symptoms such as sneezing, runny nose, and itchy or watery eyes.
-
B.
Allegra
Allegra is a widely used over-the-counter antihistamine medication for relieving allergy symptoms such as sneezing, runny nose, and itchy or watery eyes.
-
C.
Benadryl
Benadryl is a widely used over-the-counter antihistamine medication commonly taken to relieve allergy symptoms such as sneezing, itching, and runny nose.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Auscitain
An Auscitain is a resident or native of Auch, a historic town in the Occitanie region of southwestern France.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
H1 receptor antagonist
ⓘ
non-sedating antihistamine ⓘ pharmaceutical drug ⓘ second-generation antihistamine ⓘ |
| actsOn | histamine H1 receptor ⓘ |
| belongsToClass | piperidine antihistamines ⓘ |
| discoveredAs | second-generation derivative of first-generation antihistamines ⓘ |
| eliminationHalfLife | long half-life of active metabolite carebastine ⓘ |
| hasActiveMetabolite | carebastine ⓘ |
| hasAdministrationAdvice | can be taken with or without food ⓘ |
| hasATCCode | R06AX22 ⓘ |
| hasContraindication | hypersensitivity to ebastine ⓘ |
| hasDosageForm |
oral suspension
ⓘ
tablet ⓘ |
| hasDrugInteraction |
CYP3A4 inhibitors
ⓘ
erythromycin ⓘ
linked to:
erythromycin A
ketoconazole ⓘ |
| hasDurationOfEffect | approximately 24 hours ⓘ |
| hasOnsetOfAction | within a few hours after oral administration ⓘ |
| hasPharmacologicalEffect |
anti-allergic effect
ⓘ
antihistaminic effect ⓘ reduction of nasal symptoms ⓘ reduction of pruritus ⓘ reduction of wheal and flare response ⓘ |
| hasProperty |
long duration of action
ⓘ
low sedative potential ⓘ minimal central nervous system penetration ⓘ once-daily dosing ⓘ |
| hasRegulatoryApproval | approved in various European and Asian countries ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSideEffect |
dizziness
ⓘ
dry mouth ⓘ headache ⓘ somnolence ⓘ |
| hasStandardDose |
10 mg once daily for allergic rhinitis in adults
ⓘ
10–20 mg once daily for chronic urticaria in adults ⓘ |
| hasTherapeuticUse |
allergic rhinitis
ⓘ
chronic urticaria ⓘ perennial allergic rhinitis ⓘ seasonal allergic rhinitis ⓘ |
| legalStatus | prescription-only medicine in many countries ⓘ |
| mayCause | QT interval prolongation in predisposed patients ⓘ |
| metabolism |
CYP3A4-mediated metabolism
ⓘ
hepatic metabolism ⓘ |
| pregnancyCategory | use with caution in pregnancy ⓘ |
| usedIn |
adult patients
ⓘ
pediatric patients above specific age thresholds ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ebastine Description of subject: Ebastine is a second-generation, non-sedating antihistamine used primarily to treat allergic rhinitis and chronic urticaria.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.